CompletedPhase 2NCT02229929
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frederique Menzaghi, PhD, DDSCara Therapeutics, Inc.
- Intervention
- Part A: Placebo(drug)
- Enrollment
- 89 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2015
Study locations (20)
- US Renal Care, Pine Bluff, Arkansas, United States
- US Renal Care, Chula Vista, California, United States
- US Renal Care, Long Beach, California, United States
- Valley Renal Medical Group, Northridge, California, United States
- Nephrology Specialists Medical Group, Inc, Orange, California, United States
- North American Research Institute, San Dimas, California, United States
- University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
- Orlando Clinical Research Center, Orlando, Florida, United States
- Pines Clinical Research, Inc., Pembroke Pines, Florida, United States
- Emory Dialysis Center at Northside, Atlanta, Georgia, United States
- Western New England Renal & Transplant Associates, PC, Springfield, Massachusetts, United States
- US Renal Care, Gallup, New Mexico, United States
- Trude Weishaupt Memorial Dialysis Center, Fresh Meadows, New York, United States
- Winthrop University Hospital, Mineola, New York, United States
- Brookview Hills Research Associates, LLC, Winston-Salem, North Carolina, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02229929 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.